IDH1 and glioblastoma: To exclude a potential confounding effect of IDH-mutant oligodendrogliomas and glioblastomas, all of which demonstrated no T2/FLAIR-mismatch sign in our study and which are known to frequently demonstrate lower ADC and higher rCBV values as compared to IDH-mutant astrocytomas,24–26 additional analysis was performed only for the subset of patients with IDH-mutant astrocytomas.